Provided by Tiger Fintech (Singapore) Pte. Ltd.

Disc Medicine

59.08
+1.743.03%
Volume:399.80K
Turnover:23.54M
Market Cap:2.05B
PE:-15.08
High:59.72
Open:57.42
Low:57.42
Close:57.34
Loading ...

Disc Medicine Inc. Files Initial Beneficial Ownership Statement for Director Nadim Ahmed

Reuters
·
Yesterday

Jean M. Franchi, CFO, Reports Disposal of Common Shares of Disc Medicine Inc

Reuters
·
15 Jul

Disc Medicine appoints Ahmed to its Board of Directors

TIPRANKS
·
14 Jul

Disc Medicine Inc. Appoints Nadim Ahmed to Board of Directors Amid Strategic Growth Initiatives

Reuters
·
14 Jul

Disc Medicine Appoints Nadim Ahmed to Its Board of Directors

THOMSON REUTERS
·
14 Jul

CEO John D. Quisel Reports Disposal of Common Shares of Disc Medicine Inc

Reuters
·
09 Jul

Disc Medicine Coverage Assumed by Morgan Stanley at Overweight

Dow Jones
·
04 Jul

Disc Medicine Price Target Maintained With a $118.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Jul

Promising Potential of Bitopertin in Treating Erythropoietic Protoporphyria Drives Buy Rating for Disc Medicine

TIPRANKS
·
03 Jul

CFO Jean M. Franchi Reports Disposal of Common Shares of Disc Medicine Inc

Reuters
·
19 Jun

Disc Medicine Price Target Maintained With a $118.00/Share by HC Wainwright & Co.

Dow Jones
·
17 Jun

Promising Potential of Disc Medicine’s Bitopertin Drives Buy Rating

TIPRANKS
·
17 Jun

Disc Medicine’s Promising Clinical Pipeline and Strong Financial Position Justify Buy Rating

TIPRANKS
·
16 Jun

Disc Medicine Inc. Unveils Presentation on Innovative Approaches to Hematologic Disorders Targeting Iron and Heme Metabolism

Reuters
·
16 Jun

Disc Medicine Inc. Unveils EHA 2025 Corporate Presentation Highlighting Investigational Agents and Clinical Program Updates

Reuters
·
16 Jun

Disc Medicine Inc. i Conducted Annual Stockholders Meeting

Reuters
·
14 Jun

Disc Medicine Announces Positive Clinical Data and Plans for NDA Submission at EHA 2025 for Bitopertin in Erythropoietic Protoporphyria

Reuters
·
12 Jun

Disc Medicine Price Target Announced at $89.00/Share by Raymond James

Dow Jones
·
12 Jun

Disc Medicine Inc : Raymond James Resumes Coverage With Strong Buy Rating; Target Price $89

THOMSON REUTERS
·
11 Jun

Chief Medical Officer William Jacob Savage Reports Disposal of Common Shares of Disc Medicine Inc

Reuters
·
10 Jun